

[View this email in your browser](#)



Randomized Trial to Prevent Vascular Events in HIV



The 7000th participant was enrolled on Thursday, September 6th!!!

Congratulations on reaching this incredible milestone and **THANK YOU** to every REPRIEVE Site Team for the tremendous effort!!!

A special shout out to the **Brigham and Women's Hospital Therapeutics CRS** team for enrolling the 7000th participant!

Trial Status

September 10th, 2018

7005 participants are enrolled

22 participants enrolled in the past week

178 participants are in screening

116 sites are open for enrollment

19 sites enrolled at least 1 participant in the past week

20 sites screened at least 1 participant in the past week

Thank you for the excellent effort that all teams are putting forth to enroll participants in REPRIEVE.

**Thank You to All Sites That Enrolled At
Least 1 Participant in the Past Week!**

Brigham and Women's Hospital Therapeutics CRS
Harbor UCLA CRS
Washington University Therapeutics (WT) CRS
University of Colorado Hospital CRS
Wits Helen Joseph Hospital CRS (Wits HJH CRS)
Barranco CRS
Chennai Antiviral Research and Treatment (CART) CRS
SOWETO
Joint Clinical Research Centre (JCRC)/Kampala CRS
Gaborone CRS
Byramjee Jeejeebhoy Government Medical College (BJMC) CRS
Trinity Health and Wellness Center
Whitman-Walker Health CRS
Thai Red Cross AIDS Research Center
UT Southwestern
U of Miami Infectious Disease Research Unit Jackson Memorial Hosp
HGNI HIV Family Care Clinic HHFCC
Tropical Medicine Foundation
Malcom Randall VA Medical Center

**REPRIEVE Leadership is excited to announce
the...**



With approximately 500 participants to enroll, we are in our final push to the finish line! The REPRIEVE Leadership Team wants to recognize the *extra* effort and cost of recruiting these final participants.

We are keeping track of enrollment from September 10th until the enrollment of the 7500th participant!

The top 3 enrolling sites over the course of the challenge, will receive **\$1000 USD**, **\$750 USD**, or **\$500 USD** respectively for the extra effort to enroll.



*Additionally, any site that enrolls more than 5 participants between September 10th and enrollment of the 7500th participant will receive **\$100 USD** for their efforts to enroll.*

Reimbursement payments will be made upon confirmation of enrollment milestones and associated effort.

December 3rd, 2018: Next DSMB Meeting

The timeline below lists important tasks and deadlines for the upcoming Data and Safety Monitoring Board (DSMB) review of the REPRIEVE trial.

Please mark these important dates in your calendar and note that **Monday, October 8th** is the data entry deadline.

Task		Deadline* (2018)
Sites	Latest date for the occurrence of an evaluation for which complete data is expected for inclusion in this DSMB review	Sep 30 (Sun)
Sites	All data for visit through Sep 30 entered into OpenClinica	Oct 8 (Mon)
Sites	All adjudication packets for potential MACE events with a work-up complete by Sep 30 submitted to DCC (MGH)**	Oct 12 (Fri)
Sites	All outstanding queries resolved	Oct 22 (Mon)
Sites	Respond to last minute outstanding queries	Nov 9 (Fri)
All	DSMB Meeting	Dec 3 (Mon)

*Deadlines are Close of Business on the given date unless otherwise noted

** Please ensure that you have responded to all queries and clarifications from the DCC regarding source documents submitted for potential adjudicated events. This will ensure that the DCC is able to submit complete packets to TIMI for adjudication prior to the DSMB.



Due to impressive retention efforts thus far in REPRIEVE, we are asking you to identify an individual from your study team to participate in a 15–30 minute phone call to review your site's current retention practices. This individual may be a coordinator, study nurse, research assistant, or person of the like who is familiar with your site's strategies and barriers.

We have had great luck with this strategy thus far and have spoken to more than 50 sites about retention, we hope to share these best practices across all sites.

If you have not already joined in this effort, please have your identified Retention Champion use [this link](#) to select their availability, or contact Emma Kileel at ekileel@mg.harvard.edu to arrange an alternative time.

We truly appreciate each site's contribution to REPRIEVE and we are enthusiastic about completing this landmark trial working in partnership with you.



Reminder About Timing of Vaccinations

With flu season approaching in the Northern Hemisphere, remember that sites may administer vaccinations on the same day as REPRIEVE study visits but please do so after any blood to be banked has been drawn.



Submit Version 4.0, LOA #1 to DAIDS PRO

Time is running out to submit Version 4.0, LOA #1 dated 05/16/2018 to the DAIDS Protocol Registration Office.

You can implement the LoA immediately upon receiving final IRB/EC and any other applicable regulatory entity approval for the LoA (without waiting for successful LoA registration).

Please keep in mind: All sites are required to submit an LoA registration packet to the DAIDS PRO. If you have any questions about registration procedures, contact the DAIDS PRO at protocol@tech-res.com or 1+301-897-1707.

REPRIEVE (A5332): Are you up to date?

For A5332 please use:

Protocol Version 4.0 dated 03/28/2018

V4 LOA #1 dated 05/16/2018

MOPS Version 4.0 dated 04/10/2018

A5332 LPC for ACTG Sites Version 4.0 dated 03/22/2018

A5332 LPC for Non-ACTG Sites Version 4.0 dated 07/23/2018

These documents are on the [A5332 PSWP](#)

Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?

For A5333s please use

Protocol Version 4.0 dated 03/28/2018

MOPS Version 4.0 dated 04/10/2018

A5333s LPC Version 4.0 dated 03/23/2018

These documents are on the [A5333s PSWP](#)

For future reference, all newsletters are available on the [REPRIEVE Website](#).

We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at reprieve.news@fstfrf.org



REPRIEVE Trial Clinical Coordinating Center

Massachusetts General Hospital
55 Fruit Street, 5LON 207
Boston, MA USA 02144

Our mailing address is:

reprieve.news@fstfrf.org

Want to change how you receive these emails?

You can [update your preferences](#) or [unsubscribe from this list](#).